Autism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Autism Drugs Pipeline Market Overview
Autism, also known as a complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication, and repetitive behaviors. Risk factors include the child’s sex, family history, fragile X syndrome, Tourette syndrome, and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.
The Autism drugs in development market research report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.
What are the key targets in the Autism pipeline products market?
The key targets in the Autism pipeline products market are 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 7, Amine Oxidase [Flavin Containing] B, Cannabinoid Receptor 1, Cannabinoid Receptor 2, D3 Dopamine Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine, and others.
Autism Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
What are the key mechanisms of action in the Autism pipeline products market?
The key mechanisms of action in the Autism pipeline products market are 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Amine Oxidase [Flavin Containing] B Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, D2 Dopamine Receptor Agonist, D3 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine Inhibitor, and others.
Autism Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
What are the key routes of administration in the Autism pipeline products market?
The key routes of administration in the Autism pipeline products market are oral, nasal, parenteral, inhalational, intramuscular, intrathecal, subcutaneous, and sublingual.
Autism Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
What are the different molecule types in the Autism pipeline products market?
The different molecule types in the Autism pipeline products market are small molecule, biologic, antibody, cell therapy, enzyme, and synthetic peptide.
Autism Pipeline Products Market Analysis by Molecule Type
To know more about molecule types, download a free report sample
Which are the major companies in the Autism pipeline products market?
Some of the major companies in the Autism pipeline products market are MD Healthcare Inc, 4D Pharma Plc, Intra-Cellular Therapies Inc, Oryzon Genomics SA, RogCon Inc, Zelira Therapeutics Ltd, AgeneBio Inc, AgoneX Biopharmaceuticals Inc, Allos Pharma Inc, and AsiaBiome.
Autism Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Scope
| Key targets | 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 7, Amine Oxidase [Flavin Containing] B, Cannabinoid Receptor 1, Cannabinoid Receptor 2, D3 Dopamine Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine, and Others |
| Key mechanism of action | 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Amine Oxidase [Flavin Containing] B Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, D2 Dopamine Receptor Agonist, D3 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine Inhibitor, and Others |
| Key routes of administration | Oral, Nasal, Parenteral, Inhalational, Intramuscular, Intrathecal, Subcutaneous, and Sublingual |
| Molecule type | Small Molecule, Biologic, Antibody, Cell Therapy, Enzyme, and Synthetic Peptide |
| Major companies | MD Healthcare Inc, 4D Pharma Plc, Intra-Cellular Therapies Inc, Oryzon Genomics SA, RogCon Inc, Zelira Therapeutics Ltd, AgeneBio Inc, AgoneX Biopharmaceuticals Inc, Allos Pharma Inc, and AsiaBiome |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Autism (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
Allos Pharma Inc
AsiaBiome
Axial Therapeutics Inc
Cennerv Pharma (S) Pte Ltd
ChunLab Inc
Cognosetta Inc
Curemark LLC
Enterin Inc
Epigen Biosciences Inc
EuMentis Therapeutics Inc
Herophilus
Hopstem Biotechnology LLC
iCELL Biotechnology Co Ltd
ImmunoBiome Inc
Immuron Ltd
Intra-Cellular Therapies Inc
Intrinsic Medicine Inc
Johnson & Johnson
Kuzani Pharmaceuticals Inc
MD Healthcare Inc
Omeros Corp
OptiNose Inc
Oryzon Genomics SA
Palisades Therapeutics
Panorama Researchama Research
Park Active Molecules
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
RogCon Inc
Rugen Therapeutics R&D (Shanghai) Co Ltd
Scioto Biosciences Inc
SciSparc Ltd
Sengenics Corp Pte Ltd
Standigm Inc
Stem Cell Medicine Ltd
Sumitomo Dainippon Pharma Co Ltd
Tempero Bio
The Greater Cannabis Company Inc
Vanda Pharmaceuticals Inc
Yamo Pharmaceuticals LLC
Zelira Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Autism pipeline products market?
The key targets in the Autism pipeline products market are5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 7, Amine Oxidase [Flavin Containing] B, Cannabinoid Receptor 1, Cannabinoid Receptor 2, D3 Dopamine Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine, and others.
-
What are the key mechanisms of action in the Autism pipeline products market?
The key mechanisms of action in the Autism pipeline products market are5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Amine Oxidase [Flavin Containing] B Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, D2 Dopamine Receptor Agonist, D3 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine Inhibitor, and others.
-
What are the key routes of administration in the Autism pipeline products market?
The key routes of administration in the Autism pipeline products market are oral, nasal, parenteral, inhalational, intramuscular, intrathecal, subcutaneous, and sublingual.
-
What are the different molecule types in the Autism pipeline products market?
The different molecule types in the Autism pipeline products market are small molecule, biologic, antibody, cell therapy, enzyme, and synthetic peptide.
-
Which are the major companies in the Autism pipeline products market?
Some of the major companies in the Autism pipeline products market are MD Healthcare Inc, 4D Pharma Plc, Intra-Cellular Therapies Inc, Oryzon Genomics SA, RogCon Inc, Zelira Therapeutics Ltd, AgeneBio Inc, AgoneX Biopharmaceuticals Inc, Allos Pharma Inc, and AsiaBiome.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Autism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Central Nervous System reports